TrialHuman vaccines & immunotherapeutics2026

Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.

Balachandra Giriappa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.